Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market ...

Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...

Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally ...

OSPOMYV™ (denosumab-dssb) injection, for subcutaneous use Ospomyv is a RANK ligand (RANKL) inhibitor indicated for treatment: SELECTED SAFETY INFORMATION CONTRAINDICATIONS These highlights do not ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...